Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAN523 is a small molecule positive allosteric modulator (PAM) of cystathionine gamma-lyase (CSE), an enzyme responsible for the endogenous production of hydrogen sulfide (H2S). By enhancing CSE activity, SAN523 increases H2S levels, which in turn inhibits the activation of the NLRP3 inflammasome. This inhibition leads to reduced secretion of pro-inflammatory cytokines, specifically IL-1β. In preclinical studies, SAN523 has demonstrated the ability to reduce inflammatory cell recruitment and cytokine levels in mouse models of MSU-induced peritonitis, suggesting potential therapeutic application in acute gout and other IL-1β-mediated inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SAN523.